INS and obesity disorder: Db/db and ob/ob mouse models of T2D and obesity treated with SGLT2i (luseogliflozin, ipragliflozin or dapagliflozin) demonstrate reduced blood glucose, augmented insulin and GLP-1 secretion, increased β-cell mass, β-cell replication and α- to β-cell conversion, and restored β-cell identity [25–30].